Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709889 · ClinicalTrials.gov registry record · Phase 1
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT02709889 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 200 participants.
The verdict
NCT02709889, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
Interventions
- DRUG Dexamethasone
- DRUG Rovalpituzumab tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2016-09-23 |
| Est. Completion | 2019-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02709889
The ClinicalTrials.gov registry entry for NCT02709889 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT02709889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02709889 about?
NCT02709889 is a clinical study titled "Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors". The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
What is the current status of trial NCT02709889?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2016-09-23. Estimated completion is 2019-08-27.
What interventions are being tested in trial NCT02709889?
The interventions under investigation include: Dexamethasone (DRUG), Rovalpituzumab tesirine (DRUG).
Who is sponsoring clinical trial NCT02709889?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.